@article{384c73994d4d42cd9cb2441820fce76e,
title = "Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma",
author = "Smyth, {Elizabeth C.} and Petty, {Russell D.}",
note = "ECS has received honoraria from Five Prime Therapeutics, Gritstone Oncology, and Celgene for advisory roles, from Servier for giving a lecture about gastro-oesophageal cancer, and from BMS for an education day on treatments in melanoma. RDP has received honoraria from Bristol-Myers Squibb and Roche for advisory roles and from Pfizer for lectures on precision cancer medicine; RDP has also received grants for clinical research from Bristol-Myers Squibb, AstraZeneca, Merck Serono, Merck & Co, Five Prime Therapeutics, and ARMO Biosciences; this research involves immunotherapies in gastric and oesophageal cancer but is not related to the clinical trial discussed in this Comment",
year = "2018",
month = jul,
day = "14",
doi = "10.1016/S0140-6736(18)31277-7",
language = "English",
volume = "392",
pages = "97--98",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10142",
}
